Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingming Zhang

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
Cell Death & Disease|February 19, 2025
Lon protease 1-mediated metabolic reprogramming promotes the progression of prostate cancerMengfei Yao, Xingming Zhang, Tianqi Wu, et al.
Immunotherapy|February 21, 2022
Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world studyHaoran Zhang, Junru Chen, Xingming Zhang, et al.
Frontiers in Pharmacology|February 4, 2022
Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysisJunru Chen, Yaowen Zhang, Xingming Zhang, et al.
The Prostate|October 28, 2024
Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patientsXinyuan Wei, Jinge Zhao, Ling Nie, et al.
Virchows Archiv : an International Journal of Pathology|April 20, 2024
Benign metastasizing fumarate hydratase (FH)-deficient uterine leiomyomas: clinicopathological and molecular study with first documentation of multi-organ metastasesXiaoxue Yin, Xiaoxia Wei, Ruqaiya Al Shamsi, et al.
Cancer Medicine|July 28, 2021
Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abirateroneSha Zhu, Yuchao Ni, Guangxi Sun, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 15, 2022
The tumor-repressing effect of CYP27A1 on renal cell carcinoma by 27-HC arising from cholesterol metabolismXingming Zhang, Xiaoxue Yin, Jindong Dai, et al.
Neoplasia (New York, N.Y.)|August 12, 2019
The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell CarcinomaGuangxi Sun, Xingming Zhang, Zhenhua Liu, et al.
Annals of Translational Medicine|July 5, 2023
Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancerZhipeng Wang, Haoyang Liu, Jinge Zhao, et al.
Oncotargets and Therapy|September 9, 2022
Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient's CDK12 Mutation: A Case ReportSha Zhu, Yige Bao, Linmao Zheng, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
Cell Death & Disease|February 19, 2025
Lon protease 1-mediated metabolic reprogramming promotes the progression of prostate cancerMengfei Yao, Xingming Zhang, Tianqi Wu, et al.
Immunotherapy|February 21, 2022
Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world studyHaoran Zhang, Junru Chen, Xingming Zhang, et al.
Frontiers in Pharmacology|February 4, 2022
Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysisJunru Chen, Yaowen Zhang, Xingming Zhang, et al.
The Prostate|October 28, 2024
Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patientsXinyuan Wei, Jinge Zhao, Ling Nie, et al.
Virchows Archiv : an International Journal of Pathology|April 20, 2024
Benign metastasizing fumarate hydratase (FH)-deficient uterine leiomyomas: clinicopathological and molecular study with first documentation of multi-organ metastasesXiaoxue Yin, Xiaoxia Wei, Ruqaiya Al Shamsi, et al.
Cancer Medicine|July 28, 2021
Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abirateroneSha Zhu, Yuchao Ni, Guangxi Sun, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 15, 2022
The tumor-repressing effect of CYP27A1 on renal cell carcinoma by 27-HC arising from cholesterol metabolismXingming Zhang, Xiaoxue Yin, Jindong Dai, et al.
Neoplasia (New York, N.Y.)|August 12, 2019
The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell CarcinomaGuangxi Sun, Xingming Zhang, Zhenhua Liu, et al.
Annals of Translational Medicine|July 5, 2023
Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancerZhipeng Wang, Haoyang Liu, Jinge Zhao, et al.
Oncotargets and Therapy|September 9, 2022
Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient's CDK12 Mutation: A Case ReportSha Zhu, Yige Bao, Linmao Zheng, et al.
Pageof 13